View in EDS

CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma.

Saved in:
Bibliographic Details
Title: CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma.
Authors: Harrison, S. J.1,2,3,4 simon.harrison@petermac.org, Touzeau, C.5,6,7, Kint, N.8, Li, K.9, Nguyen, T.4, Mayeur-Rousse, C.10, Rahman, M.1,2, Bris, Y. Le6,7,10, Er, J.1,2,11, Eugene-Lamer, J.12, Haynes, N. M.3,4, Li, J.3, Abbott, R. C.3,4, Bodet-Milin, C.6,7,13, Moreau, A.12, Letouzé, E.6,7, Lendvai, N.14, Schecter, J. M.14, Deraedt, W.5, Banerjee, A.9
Source: New England Journal of Medicine. 2/13/2025, Vol. 392 Issue 7, p677-685. 9p.
Database: Academic Search Ultimate
Description
ISSN:00284793
DOI:10.1056/NEJMoa2309728